Unknown

Dataset Information

A new ALK isoform transported by extracellular vesicles confers drug resistance to melanoma cells.


ABSTRACT:

Background

Drug resistance remains an unsolved clinical issue in oncology. Despite promising initial responses obtained with BRAF and MEK kinase inhibitors, resistance to treatment develops within months in virtually all melanoma patients.

Methods

Microarray analyses were performed in BRAF inhibitor-sensitive and resistant cell lines to identify changes in the transcriptome that might play a role in resistance. siRNA approaches and kinase inhibitors were used to assess the involvement of the identified Anaplastic Lymphoma Kinase (ALK) in drug resistance. The capability of extracellular vesicles (EVs) to transfer drug resistant properties was investigated in co-culture assays.

Results

Here, we report a new mechanism of acquired drug resistance involving the activation

SUBMITTER: Cesi G 

PROVIDER: S-EPMC6172729 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature